IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Evoq Remedies IPO is a Fixed Price listing on BSE SME exchange. The company is based in Ahmedabad and caters to Pharmaceutical sector. Swastika Investmart is the merchant banker of Evoq Remedies IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 24th February 2022.
Evoq Remedies IPO posted revenues of ₹ 11.53 crores and PAT of ₹ 1.03 crores in FY22 on annualised basis.
Revenue:
₹ 11.53 Cr.
EBITDA Margin:
2.37
% 
Net Worth: ₹ 13.28 Cr.
Market Capitalisation:
₹ 36.72 Cr.
P/E:
33.75 times
P/BV: 1.60 times
EV/EBITDA: 130.06 times
Financial results of Evoq Remedies IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Feb-22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 26.61 | 8.05 | 5.65 | 2.15 | |
| Net Worth | 13.28 | 0.74 | 0.02 | 0.02 | |
| Total Debt | 0.74 | 0.01 | 0.01 | [●] | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
10.57
11.53 |
10.02 | 9.07 | 3.25 | |
EBITDA
EBITDA on annualised basis |
0.25
0.27 |
0.95 | [●] | 0.02 | |
PAT
PAT on annualised basis |
0.94
1.03 |
0.71 | [●] | 0.01 | |
Evoq Remedies IPO PAT Margin is 8.89 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Evoq Remedies IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Feb-22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|
| EBITDA Margin (%) | 2.37 | 9.48 | [●] | 0.62 |
| PAT Margin (%) | 8.89 | 7.09 | [●] | 0.31 |
| EPS (₹) | 5.52 | 10.05 | [●] | 0.16 |
| ROE (%) | 7.08 | 95.95 | [●] | 50.00 |
| ROCE (%) | [●] | [●] | [●] | [●] |
| ROA (%) | 3.53 | 8.82 | [●] | 0.47 |
| Debt to Equity | 0.06 | 0.01 | 0.50 | [●] |
The market Capitalisation of Evoq Remedies IPO is ₹ 36.72 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Evoq Remedies IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Evoq Remedies IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Evoq Remedies IPO is ₹ 36.72 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Evoq Remedies IPO has a Price-to-Earnings (PE) ratio of 33.75 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Evoq Remedies IPO reported revenue of ₹ 11.53 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Evoq Remedies IPO provide insights into sales growth, market demand, and business scalability.
Evoq Remedies recorded an EBITDA of ₹ 0.27 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Evoq Remedies Profit After Tax (PAT) is ₹ 1.03 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 11.53 Cr.
EBITDA Margin:
2.37
%
Net Worth: ₹ 13.28 Cr.
Market Capitalisation:
₹ 36.72 Cr.
P/E:
33.75 times
P/BV: 1.60 times
EV/EBITDA: 130.06 times
Evoq Remedies operates in Pharmaceutical and Trading House Of Pharmaceuticals Raw Materials. The Issue is listed on BSE SME in Mar, 2022. Evoq Remedies IPO size was 9.72 with Issue price of 27.00 .
Merchant Banker(s) of Evoq Remedies IPO: Swastika Investmart Limited
Evoq Remedies IPO subscription was 1.67 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Evoq Remedies IPO listed at a listing price of 23.75 against the offer price of 27.00.
The current market price of Evoq Remedies is 3.25.
Why Us?
